Race Oncology Ltd. (AU:RAC) has released an update.
Race Oncology Ltd reported a productive quarter, successfully completing key safety studies for its cancer treatment drug RC220 bisantrene and securing extensions for Orphan Drug and Rare Paediatric Disease Designations from the US FDA. With a solid financial boost due to shareholder bonus option conversions, raising $5 million and increasing net cash to $17.19 million, Race is gearing up to initiate human clinical trials in 2024. The company also announced promising preclinical results showing bisantrene’s potential when used with other anticancer agents, broadening its applicability in cancer treatment.
For further insights into AU:RAC stock, check out TipRanks’ Stock Analysis page.
